Serum calprotectin correlates with risk and disease severity of ankylosing spondylitis and its change during first month might predict favorable response to treatment
Serum calprotectin correlates with risk and disease severity of ankylosing spondylitis and its change during first month might predict favorable response to treatment
复制标题
DOI：
10.1080/14397595.2018.1519103
复制
发表时间：
2019-09-03
影响因子：
2.2
通讯作者：
Zhang, Weiguo
中科院分区：
文献类型：
--
作者：
Hu, Hua;Du, Fei;Zhang, Weiguo
目的：调查血清钙卫蛋白与强直性脊柱炎（AS）风险和严重程度的关系，并研究其预测治疗反应的价值。方法：262 名 AS 患者和 260 名健康对照者 (HC) 纳入本研究。 142 名活动性 AS 患者接受药物治疗，并根据 ASAS 40 改善标准评估临床反应。在入组时从 AS 患者和 HC 以及治疗后第 1、3 和 6 个月时从 142 名活动性 AS 患者采集了 4 ml 血样。并且，通过酶联免疫吸附测定（ELISA）评估血清钙卫蛋白、IL-1β、IL-17和TNF-α表达。结果：AS患者钙卫蛋白表达显着高于HC，受试者工作曲线（ROC）分析显示基线钙卫蛋白对AS具有重要的诊断价值。钙卫蛋白水平与CRP、ESR、PGA、疼痛VAS、BASDAI和BASFI评分呈正相关，且钙卫蛋白水平较高的患者IL-1β、IL-17和TNF-α表达升高。治疗后，活动性 AS 患者的钙卫蛋白水平从基线到 1、3 或 6 个月显着下降。此外，达到 ASAS 40 的患者在第一个月内钙卫蛋白水平变化较大，第一个月钙卫蛋白的变化可以预测达到 ASAS 40 的患者，AUC 为 0.691。结论：血清钙卫蛋白水平可能是 AS 风险和严重程度的一个有前途的生物标志物，治疗后第一个月钙卫蛋白的变化可能预测活动性 AS 患者更有利的治疗反应。
Objectives: To investigate the association of serum calprotectin with risk and severity of ankylosing spondylitis (AS), and to study its value for predicting treatment responses. Methods: 262 AS patients and 260 health controls (HCs) were enrolled in this study. 142 active AS patients were treated by pharmaceutical therapy and clinical response was evaluated according to ASAS 40 improvement criteria. 4 ml blood sample was collected from AS patients and HCs at enrollment, and from 142 active AS patients at month 1, 3 and 6 after treatments. And, serum calprotectin, IL-1 beta, IL-17 and TNF-alpha expressions were assessed by Enzyme-linked immune sorbent assay (ELISA). Results: The expression of calprotectin in AS patients was remarkably higher compared to HCs, and Receiver Operating Curve (ROC) analysis showed that baseline calprotectin was of great diagnostic value for AS. Calprotectin level was positively correlated with CRP, ESR, PGA, pain VAS, BASDAI and BASFI scores, moreover, patients with higher calprotectin levels were with elevated expressions of IL-1 beta, IL-17 and TNF-alpha. Post-treatment, the calprotectin levels of active AS patients notably decreased from baseline to 1, 3 or 6 month. Additionally, patients achieved ASAS 40 were with more considerable change in calprotectin level during first month, and change of calprotectin during first month could predict patients achieving ASAS 40 with AUC of 0.691. Conclusion: Serum calprotectin level could be a promising biomarker for risk and severity of AS, and change of calprotectin during first month post-treatment might predict more favorable treatment response in active AS patients.